Compare Sun Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs SANOFI INDIA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA SANOFI INDIA SUN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 28.6 43.9 65.1% View Chart
P/BV x 2.9 8.0 35.9% View Chart
Dividend Yield % 0.6 1.1 51.0%  

Financials

 SUN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
SANOFI INDIA
Dec-18
SUN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6796,840 9.9%   
Low Rs3754,630 8.1%   
Sales per share (Unadj.) Rs121.11,203.1 10.1%  
Earnings per share (Unadj.) Rs13.4165.3 8.1%  
Cash flow per share (Unadj.) Rs20.7209.9 9.9%  
Dividends per share (Unadj.) Rs2.7584.00 3.3%  
Dividend yield (eoy) %0.51.5 35.6%  
Book value per share (Unadj.) Rs172.6963.6 17.9%  
Shares outstanding (eoy) m2,399.2623.03 10,418.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.8 91.3%   
Avg P/E ratio x39.434.7 113.6%  
P/CF ratio (eoy) x25.527.3 93.3%  
Price / Book Value ratio x3.16.0 51.3%  
Dividend payout %20.650.8 40.4%   
Avg Mkt Cap Rs m1,264,650132,078 957.5%   
No. of employees `00017.53.3 530.2%   
Total wages/salary Rs m59,6714,068 1,466.8%   
Avg. sales/employee Rs Th16,608.18,393.8 197.9%   
Avg. wages/employee Rs Th3,409.61,232.4 276.7%   
Avg. net profit/employee Rs Th1,833.81,153.0 159.0%   
INCOME DATA
Net Sales Rs m290,65927,708 1,049.0%  
Other income Rs m10,255897 1,143.2%   
Total revenues Rs m300,91428,605 1,052.0%   
Gross profit Rs m63,0766,235 1,011.6%  
Depreciation Rs m17,5331,027 1,707.2%   
Interest Rs m5,5537 79,321.4%   
Profit before tax Rs m50,2466,098 824.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0092,292 262.2%   
Profit after tax Rs m32,0933,806 843.2%  
Gross profit margin %21.722.5 96.4%  
Effective tax rate %12.037.6 31.8%   
Net profit margin %11.013.7 80.4%  
BALANCE SHEET DATA
Current assets Rs m310,69215,922 1,951.3%   
Current liabilities Rs m173,3966,235 2,781.0%   
Net working cap to sales %47.235.0 135.1%  
Current ratio x1.82.6 70.2%  
Inventory Days Days9964 155.6%  
Debtors Days Days11221 534.7%  
Net fixed assets Rs m232,4777,539 3,083.7%   
Share capital Rs m2,399230 1,043.2%   
"Free" reserves Rs m411,69121,962 1,874.6%   
Net worth Rs m414,09122,192 1,865.9%   
Long term debt Rs m15,2260-   
Total assets Rs m646,93829,839 2,168.1%  
Interest coverage x10.0872.1 1.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.9 48.4%   
Return on assets %5.812.8 45.5%  
Return on equity %7.817.2 45.2%  
Return on capital %10.227.5 37.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,0257,587 870.2%   
Fx outflow Rs m38,6107,145 540.4%   
Net fx Rs m27,415442 6,202.5%   
CASH FLOW
From Operations Rs m21,9653,739 587.4%  
From Investments Rs m-6,813-731 931.9%  
From Financial Activity Rs m-27,305-1,972 1,384.6%  
Net Cashflow Rs m-8,4421,036 -814.8%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.1 14.4 35.6%  
FIIs % 23.0 14.6 157.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.5 79.0%  
Shareholders   133,026 15,184 876.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Infosys & Axis Bank Top Gainers(12:30 pm)

Share markets in India have extended early gains and are presently trading on a strong note.

Related Views on News

GRANULES INDIA at All Time High; BSE HEALTHCARE Index Up 0.8% (Market Updates)

Jul 15, 2020 | Updated on Jul 15, 2020

GRANULES INDIA share price has hit an all time high at Rs 249 (up 4.0%). The BSE HEALTHCARE Index is up by 0.8%. Among the top gainers in the BSE HEALTHCARE Index today are GRANULES INDIA (up 4.0%) and SANOFI INDIA (up 0.7%). The top losers include LUPIN and WOCKHARDT (down 0.1%).

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 15, 2020 01:13 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS